PharmaResearch&#39;s Rejuran / Provided by PharmaResearch

PharmaResearch is turning heads in the industry with its impressive first-quarter operating profit margin of nearly 40%. As traditional prescription drug markets face declining profitability due to price cuts and tighter reimbursement regulations, analysts point to the non-reimbursable medical aesthetics market as an emerging high-profit business model.

According to industry reports on Tuesday, PharmaResearch posted consolidated sales of 146.1 billion KRW (about 97.9 million USD) and operating profits of 57.3 billion KRW (about 38.4 million USD) in Q1. These figures represent year-over-year increases of 25% and 28%, respectively. The company's 39.2% operating profit margin is exceptional, especially considering that most traditional Korean pharmaceutical companies typically see single-digit to low double-digit margins. This performance also surpassed market expectations.

The medical device sector is driving this growth. Sales in this segment hit 79.5 billion KRW (about 53.3 million USD), up 14.5% from last year. Domestic sales were particularly strong, jumping 20.9% to 58.4 billion KRW (about 39.1 million USD) and boosting overall performance. The company's flagship product, Rejuran skin booster, is Korea's first injectable using a regenerative substance derived from salmon DNA. It has gained market share thanks to over a decade of clinical data and strong brand trust.

PharmaResearch reports that demand from foreign patients, which had dipped earlier this year, is now rebounding. A company spokesperson noted that while it saw a slight decline in foreign patients in January and February, domestic demand remained strong. Since March, medical tourism has picked up again, and they're seeing continued orders from Europe. It expects this growth trend to continue into Q2.

Export sales climbed 30% year-over-year to 58.8 billion KRW (about 39.4 million USD), now accounting for 40% of total sales. The cosmetics division also showed robust growth. Q1 cosmetics sales surged 51% to 42.2 billion KRW (about 28.2 million USD), with exports in this category jumping 55.8% to 26.9 billion KRW (about 18 million USD). Analysts suggest that the company's strong reputation in clinical treatments is driving growth in its dermacosmetics sales.

Highlighting Rejuran's competitive edge, a company representative stated that it controls the entire process, from raw material extraction and purification to production. The trust they've built domestically is now resonating with medical professionals and consumers overseas. This year, the company plans to ramp up medical device exports, particularly to Western Europe, while expanding both online and offline distribution for Rejuran cosmetics.

However, intensifying market competition remains a concern. The booming skin booster market has attracted numerous similar products, and potential regulatory changes in key export markets loom on the horizon.

An industry expert commented that PharmaResearch's performance clearly illustrates the ongoing structural shift in the pharmaceutical and biotech sectors, with companies pivoting from traditional prescription drugs to non-reimbursable medical aesthetics.

PharmaResearch is turning heads in the industry with its impressive first-quarter operatin …

PharmaResearch Posts Near-40% Operating Margin as Rejuran and Medical Aesthetics Drive Growth